NHS patients could face restricted access to cutting-edge medicines as new pricing arrangements threaten to significantly increase the health service's drug bill, the Nuffield Trust has warned.
The current Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), which has helped control NHS medicine costs for five years, expires at the end of 2023. Under this arrangement, pharmaceutical companies rebate a portion of their branded medicine sales back to the NHS, effectively capping how much the health service spends on drugs each year.
However, the new agreement being negotiated appears likely to allow drug companies to keep a larger share of their sales revenue, meaning higher direct costs for the NHS. Whilst negotiations continue, early indications suggest this could place considerable strain on already stretched NHS budgets.
The implications for patients could be serious. Higher medicine costs may force difficult rationing decisions, potentially delaying access to new treatments or limiting their availability. This comes as the NHS already faces record waiting lists exceeding 7.5 million people, widespread staff shortages, and mounting financial pressures across all services.
The Government faces a challenging balancing act in these negotiations. Ministers must ensure the NHS can afford essential medicines whilst maintaining incentives for pharmaceutical companies to invest in UK-based research and development. The pharmaceutical sector contributes significantly to the British economy and supports thousands of jobs in research, manufacturing and related industries.
The Department of Health and Social Care has not yet confirmed details of the replacement scheme, but the Nuffield Trust's intervention highlights growing concerns about NHS sustainability. Opposition parties are expected to scrutinise any final agreement closely, particularly regarding how it might affect patient access to vital medications and impact the health service's already constrained finances.